“A primary Nature Medicine study developed and evaluated EAGLE, an AI model for detecting esophageal malignancy and precancerous lesions from noncontrast chest CT.”

Checks out so far. 3 hold up so far.

0.8386 under ledger-default@0.3.0 at snapshot 27745 for all claims together. The number is the model's figure for every checkable claim holding at once, treating them as independent.

The statement as a whole, read from the 3 claims below. Each claim is scored on its own; this reading only counts them. Provisional until audited.

Review 50% done · 25% counted in review coverage · 25% by the claims' own author only (3 claims, 12 checks)

Share:

Checked in Galedra: score 0.84, mostly supported · not yet reviewed by anyone else “A primary Nature Medicine study developed and evaluated EAGLE, an AI model for detecting esophageal malignancy and precancerous lesions from noncontrast chest CT.” https://galedra.org/investigations/01a0eae2-3009-739c-b7d6-9d4976b3cf74

“The EAGLE model was trained on 6,813 patients and validated across 12 centers in three countries involving 80,612 patients.”

Supported · 0.9734 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

2 of 4 review checks done · 1 counted · 1 by the author only

See the evidence · Claim card

“In the study’s eight-center external CT test cohorts, EAGLE achieved 98.5% specificity, 90.0% cancer sensitivity and 52.5% precancerous-lesion sensitivity.”

Supported · 0.9781 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

2 of 4 review checks done · 1 counted · 1 by the author only

See the evidence · Claim card

“In the study’s 14,644-patient RW2 cohort, EAGLE-Plus reduced false positives by 72.7% while maintaining comparable sensitivity.”

Supported · 0.8808 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

2 of 4 review checks done · 1 counted · 1 by the author only

See the evidence · Claim card